Literature DB >> 2340500

Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy.

G J Hauser1, J K McIntosh, W D Travis, S A Rosenberg.   

Abstract

The role of oxygen free radicals in the toxicity and antitumor effect of tumor necrosis factor was investigated in vivo. Treatment of non-tumor-bearing mice and mice bearing methylcholanthrene-induced sarcomas with bovine CuZn superoxide dismutase or recombinant human CuZn superoxide dismutase afforded significant protection to these mice from a subsequent challenge with recombinant human tumor necrosis factor (rhTNF). Pretreatment with superoxide dismutase increased survival rates, at 48 h after rhTNF injection, in non-tumor-bearing mice from 22 to 65% and in tumor-bearing mice from 25 to 79%. Protection from rhTNF toxicity was not associated with any reduction in the therapeutic efficacy of rhTNF against methylcholanthrene-induced sarcomas in either s.c. or visceral sites (e.g., cure rates in mice bearing s.c. tumors which were treated with rhTNF without or with superoxide dismutase pretreatment were 18 and 39%, respectively). Furthermore, the administration of L-buthionine-S,R-sulfoximine, an inhibitor of glutathione synthesis, to mice bearing s.c. tumors resulted in increased rhTNF toxicity but no improvement in therapeutic efficacy. Tumor necrosis factor toxicity is mediated by the release of oxygen free radicals, probably from activated neutrophils, but its antitumor effect in methylcholanthrene-induced sarcomas is not dependent on their generation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2340500

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Glutathione and the rate of cellular proliferation determine tumour cell sensitivity to tumour necrosis factor in vivo.

Authors:  E Obrador; J Navarro; J Mompo; M Asensi; J A Pellicer; J M Estrela
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Subcutaneous administration of bovine superoxide dismutase protects lungs from radiation-induced lung injury.

Authors:  Vlado Antonic; Zahid N Rabbani; Isabel L Jackson; Zeljko Vujaskovic
Journal:  Free Radic Res       Date:  2015-08-11

3.  Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants.

Authors:  J A Barbara; W B Smith; J R Gamble; X Van Ostade; P Vandenabeele; J Tavernier; W Fiers; M A Vadas; A F Lopez
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

4.  The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

Authors:  J W Baars; C E Hack; J Wagstaff; A J Eerenberg-Belmer; G J Wolbink; L G Thijs; R J Strack van Schijndel; H L van der Vall; H M Pinedo
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

5.  Circadian dynamics of tumor necrosis factor alpha (cachectin) lethality.

Authors:  W J Hrushesky; T Langevin; Y J Kim; P A Wood
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

6.  Superoxide dismutases in relation to the overall survival of colorectal cancer patients.

Authors:  A M Janssen; C B Bosman; C F Sier; G Griffioen; F J Kubben; C B Lamers; J H van Krieken; C J van de Velde; H W Verspaget
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

7.  Polyoxyethylene-modified superoxide dismutase reduces side effects of adriamycin and mitomycin C.

Authors:  S Kawasaki; S Akiyama; T Kurokawa; M Kataoka; K Dohmitsu; K Kondoh; M Yamauchi; K Ito; T Watanabe; S Sugiyama
Journal:  Jpn J Cancer Res       Date:  1992-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.